Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Tohen, M. Articles by Tollefson, G. A. Search for Related Content PubMed Citation Articles by Tohen, M. Articles by Tollefson, G. A. Amphetamines Anticonvulsants Atypical Neuroleptics

Olanzapine Versus Divalproex in the Treatment of Acute Mania

OBJECTIVE: The effects of olanzapine and divalproex for the treatment of mania were compared in a large randomized clinical trial. METHOD: A 3-week, randomized, double-blind trial compared flexibly dosed olanzapine (5–20 mg/day) to divalproex (500–2500 mg/day in divided doses) for the treatment of patients hospitalized for acute bipolar manic or mixed episodes. The Young Mania Rating Scale and the Hamilton Depression Rating Scale were used to quantify manic and depressive symptoms, respectively. Safety was assessed with several measures. RESULTS: The protocol defined baseline-to-endpoint improvement in the mean total score on the Young Mania Rating Scale as the primary outcome variable. The mean Young Mania Rating Scale score decreased by 13.4 for patients treated with olanzapine (N=125) and 10.4 for those treated with divalproex (N=123). A priori categorizations defined response and remission rates: 54.4% of olanzapine-treated patients responded (50% reduction in Young Mania Rating Scale score), compared to 42.3% of divalproex-treated patients; 47.2% of olanzapine-treated patients had remission of mania symptoms (endpoint Young Mania Rating Scale 12), compared to 34.1% of divalproex-treated patients. The decrease in Hamilton depression scale score was similar in the two treatment groups. Completion rates for the 3-week study were similar in both groups. The most common treatment-emergent adverse events (incidence >10%) occurring more frequently during treatment with olanzapine were dry mouth, increased appetite, and somnolence. For divalproex, nausea was more frequently observed. The average weight gain with olanzapine treatment was 2.5 kg, compared to 0.9 kg with divalproex treatment. CONCLUSIONS: The olanzapine treatment group had significantly greater mean improvement of mania ratings and a significantly greater proportion of patients achieving protocol-defined remission, compared with the divalproex treatment group. Significantly more weight gain and cases of dry mouth, increased appetite, and somnolence were reported with olanzapine, while more cases of nausea were reported with divalproex.

This article has been cited by other articles:

				H. Scherk, F. G. Pajonk, and S. Leucht Second-Generation Antipsychotic Agents in the Treatment of Acute Mania: A Systematic Review and Meta-analysis of Randomized Controlled Trials Arch Gen Psychiatry, April 1, 2007; 64(4): 442 - 455. [Abstract] [Full Text] [PDF]

				G. S. Sachs Bipolar Disorder Clinical Synthesis: Where Does the Evidence Lead? Focus, January 1, 2007; 5(1): 3 - 13. [Abstract] [Full Text] [PDF]

				R. M. A. Hirschfeld Guideline Watch (November 2005): Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd Edition Focus, January 1, 2007; 5(1): 34 - 39. [Abstract] [Full Text] [PDF]

				Bibliography BIPOLAR DISORDER Focus, January 1, 2007; 5(1): 40 - 43. [Full Text] [PDF]

				J. Cookson and B. Elliott The use of anticonvulsants in the aftermath of mania. J Psychopharmacol, March 1, 2006; 20(2_suppl): 23 - 30. [Abstract] [PDF]

				M. Tohen, W. Greil, J. R. Calabrese, G. S. Sachs, L. N. Yatham, B. M. Oerlinghausen, A. Koukopoulos, G. B. Cassano, H. Grunze, R. W. Licht, et al. Olanzapine Versus Lithium in the Maintenance Treatment of Bipolar Disorder: A 12-Month, Randomized, Double-Blind, Controlled Clinical Trial Am J Psychiatry, July 1, 2005; 162(7): 1281 - 1290. [Abstract] [Full Text] [PDF]

				F. T. Lewis Demystifying the Disease State: Understanding Diagnosis and Treatment Across the Bipolar Spectrum Journal of the American Psychiatric Nurses Association, June 1, 2004; 10(3_suppl): S6 - S15. [Abstract] [PDF]

				M. S. Bauer and L. Mitchner What Is a "Mood Stabilizer"? An Evidence-Based Response Am J Psychiatry, January 1, 2004; 161(1): 3 - 18. [Abstract] [Full Text] [PDF]

				M. Tohen, J. F. Goldberg, A. M. Gonzalez-Pinto Arrillaga, J. M. Azorin, E. Vieta, M.-C. Hardy-Bayle, W. B. Lawson, R. A. Emsley, F. Zhang, R. W. Baker, et al. A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania Arch Gen Psychiatry, December 1, 2003; 60(12): 1218 - 1226. [Abstract] [Full Text] [PDF]

				M. Tohen, E. Vieta, J. Calabrese, T. A. Ketter, G. Sachs, C. Bowden, P. B. Mitchell, F. Centorrino, R. Risser, R. W. Baker, et al. Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression Arch Gen Psychiatry, November 1, 2003; 60(11): 1079 - 1088. [Abstract] [Full Text] [PDF]

				M. Tohen, T. A. Ketter, C. A. Zarate, T. Suppes, M. Frye, L. Altshuler, J. Zajecka, L. M. Schuh, R. C. Risser, E. Brown, et al. Olanzapine Versus Divalproex Sodium for the Treatment of Acute Mania and Maintenance of Remission: A 47-Week Study Am J Psychiatry, July 1, 2003; 160(7): 1263 - 1271. [Abstract] [Full Text] [PDF]

				M.-L. Lu Olanzapine reduces mania more effectively than divalproex, but has more adverse effects Evid. Based Ment. Health, February 1, 2003; 6(1): 28 - 28. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us